ArticleCureus2025
Impact of Preoperative Opioid Use in Lung Transplant Recipients: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose The impact of preoperative opioids on lung transplant outcomes has not been well established. This study explores survival rates and mortality risk factors in lung transplant recipients with preoperative opioid prescriptions. Methods A single-institutional lung transplant database (2018-2024) was used to collect data on patient characteristics, pretransplant laboratory values, and postoperative outcomes. Opioid prescriptions were normalized to morphine equivalents (MEs). Chi-squared, one-way ANOVA, Kruskal-Wallis, Kaplan-Meier, and Wilcoxon signed-rank tests were used for analysis. Results Among 399 lung transplant recipients, 188 (47.1%) reported opioid use within 30 days before transplantation: 115 (61.2%) had ME ≥ 0.1 mg (high-ME), and 73 (38.8%) had ME < 0.1 mg (low-ME). There was no significant difference in one-year survival between the high-ME cohort and their counterparts (83.8% vs. 86.7% (low-ME) vs. 90.5% (no ME), p = 0.86). Intensive care unit (ICU) stay (median: 10 (5-20, interquartile range (IQR)) vs. 7 (5-13, IQR, low-ME) vs. 7 (4-14, IQR, no ME) days, p = 0.046) and hospital stay (median: 21 (13-38, IQR) vs. 17 (11-31, IQR, low-ME) vs. 16 (11-27, IQR, no ME) days, p = 0.007) were significantly longer in the high-ME cohort. The high-ME cohort had a higher incidence of primary graft dysfunction (PGD) (hazard ratio, or HR 1.84 (1.17-2.89, 95% CI), p = 0.008) and PGD Grade 3 (HR 2.16 (1.18-3.97, 95% CI), p = 0.01). Conclusions Preoperative opioid use in lung transplant patients is an independent risk factor for post-transplant PGD risk and a predictor of prolonged hospital stay. Weaning of opioids prior to lung transplantation may limit prolonged hospital stay and ventilation use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.